Novo Nordisk A/S Stock Forecast
NYSE: NVOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 9, 1:57 PM ET
NVO analyst consensus
Consensus (14 analysts)
hold
Avg. price target
$46.07+19.83%
- Strong buy 0
- Buy 3
- Hold 10
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 14 Wall Street analysts covering Novo Nordisk A/S (2026-10-07), 3 rate the stock a buy or strong buy, 10 rate it a hold and 1 rate it a sell or strong sell, for a consensus rating of "hold". The average 12-month price target is $46.07, with a high estimate of $61.82 and a low estimate of $39.76. The average target implies upside of 19.8% from the current price of $38.45.
The spread between the highest and lowest targets is 55.5%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for NVO.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 3 | 21% |
| Hold | 10 | 71% |
| Sell | 1 | 7% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $39.76 | +3.42% |
| Average target | $46.07 | +19.83% |
| High target | $61.82 | +60.80% |